


PHARMACEUTICAL 2022

Seres Therapeutics Inc. Rank 181 of 475









Seres Therapeutics Inc. Rank 181 of 475

The relative strengths and weaknesses of Seres Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Seres Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 184% points. The greatest weakness of Seres Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 45% points.

The company's Economic Capital Ratio, given in the ranking table, is -42%, being 234% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	303,628
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	82,258
Liabilities, Non-Current	29,453
Other Assets	33,293
Other Compr. Net Income	-13
Other Expenses	-1,732
Other Liabilities	111,641
Other Net Income	-1,085
Property and Equipment	17,938
Research and Development	141,891
Revenues	144,927
Selling, General and Administrative Expense	69,261

Output Variable	Value in 1000 USD
Assets	354,859
Liabilities	223,352
Expenses	209,420
Stockholders Equity	131,507
Net Income	-65,578
Comprehensive Net Income	-65,584
Economic Capital Ratio	-42%

